Articles from Fulgent Genetics, Inc.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its fourth quarter and full year ended December 31, 2024.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its fourth quarter and full year 2024 financial results before the market opens on Friday, February 28, 2025. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2024.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that members of its management team are scheduled to present at the following upcoming investor conferences:

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced it has been awarded a five-year contract by the U.S. Department of Veterans Affairs (VA) to provide hereditary cancer, pharmacogenetic and other genetic testing to Veterans.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its third quarter 2024 financial results before the market opens on Friday, November 8, 2024. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its second quarter ended June 30, 2024.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2024 financial results before the market opens on Friday, August 2, 2024. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2024.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2024 financial results before the market opens on Friday, May 3, 2024. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its fourth quarter and full year ended December 31, 2023.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that it will release its fourth quarter and full year 2023 financial results before the market opens on Wednesday, February 28, 2024. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that members of its management team are scheduled to participate in the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced data from two poster presentations being presented tomorrow, November 4, 2023, at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, CA.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2023.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced two upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, to be held virtually and at the San Diego Convention Center from November 1 to 5, 2023.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that it will release its third quarter 2023 financial results before the market opens on Friday, November 3, 2023. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its second quarter ended June 30, 2023.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that it will release its second quarter 2023 financial results before the market opens on Friday, August 4, 2023. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced data from a Phase 1/1b clinical study of FID-007 in treating various solid tumors was presented in a poster session at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, IL on June 3, 2023.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that Phase 1/1b clinical data on its lead therapeutic development candidate, FID-007, to treat various solid tumors, will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting at 8:00 a.m. Central Time on June 3, 2023 in Chicago, Illinois.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2023.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that it will release its first quarter 2023 financial results before the market opens on Friday, May 5, 2023. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent”, or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its fourth quarter and full year ended December 31, 2022.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced the immediate availability of their new Beacon787 expanded carrier screening panel. Beacon787 will include a total of 787 genes associated with autosomal recessive and X-linked conditions. Included in this panel are all of the American College of Medical Genetics and Genomics (ACMG) tier 3 genes, which ACMG published in their latest practice guideline for carrier screening, recommending that all pregnant patients and those planning a pregnancy be offered this set of genes as an equitable, pan-ethnic screening approach. The ACMG list includes genes with carrier frequency of >1/200 for autosomal recessive conditions and disease prevalence of >1/40,000 for X-linked conditions. Leveraging Fulgent’s proprietary platform and informatics, Beacon frequently excels as it relates to analytical detection rates, ability to discern pseudogenes, and reliable copy number calls.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent” or the “Company”), a technology-based genetic testing and therapeutics company focused on transforming patient care in oncology, infectious and rare diseases, reproductive health, and pathology, today announced that it will release its fourth quarter and full year 2022 financial results after the market closes on Tuesday, February 28, 2023. Management will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent Genetics”, “Fulgent” or the “company”) today announced the addition of Reggie Groves to its board of directors, effective January 3, 2023.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent” or the “Company”), a technology-based genetic testing and therapeutics company focused on transforming patient care in oncology, infectious and rare diseases, reproductive health, and pathology, today announced that members of its management team are scheduled to participate in the Piper Sandler 34th Annual Healthcare Conference on Wednesday, November 30, 2022.

Fulgent Genetics, Inc. (NASDAQFLGT), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, announced today that it has completed an acquisition of Fulgent Pharma Holdings, Inc. (“Fulgent Pharma”), an independent clinical-stage, therapeutics development company focused on the development of innovative cancer treatments. Under the terms of the agreement, Fulgent Genetics acquired Fulgent Pharma for a total purchase price of approximately $100 million, subject to adjustments, to be paid with a combination of cash on hand and shares of common stock of Fulgent Genetics.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent Genetics”, “Fulgent”, or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced financial results for its third quarter ended September 30, 2022.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent Genetics” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that members of its management team are scheduled to participate in Credit Suisse’s 31st Annual Healthcare Conference on Tuesday, November 8, 2022.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent Genetics” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will release its third quarter 2022 financial results after the market closes on Monday November 7, 2022. Management will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent Genetics”, “Fulgent”, or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced financial results for its second quarter ended June 30, 2022.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent Genetics”, “Fulgent” or the “company”) today announced the addition of two therapeutic industry veterans to its board of directors. Dr. Michael Nohaile, Chief Scientific Officer of Generate Biomedicines (“Generate”), and Dr. Leonard Post, Chief Scientific Officer of Vivace Therapeutics (“Vivace”), who joined the company’s Board of Directors, effective August 1, 2022.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent Genetics”, “Fulgent”, or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced it has launched a test for monkeypox that leverages the U.S. Centers for Disease Control and Prevention’s (CDC) orthopoxvirus test, which detects non-smallpox related orthopoxviruses, including monkeypox. Fulgent will begin accepting specimens for testing next week from healthcare providers, clinics and state laboratories.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent Genetics” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will release its second quarter 2022 financial results after the market closes on Thursday, August 4, 2022. The company’s Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim, Chief Commercial Officer Brandon Perthuis, and Chief Medical Officer Dr. Larry Weiss will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent Genetics”, “Fulgent”, or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced financial results for its first quarter ended March 31, 2022.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent Genetics”, “Fulgent”, or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced a number of promotions and appointments across its leadership team.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent Genetics”, “Fulgent”, or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced the opening of its new state-of-the-art oncology laboratory in El Monte, California, near the Company’s global headquarters in Temple City. This new CLIA-certified lab will enable Fulgent to expand its capabilities in somatic molecular diagnostics and cancer testing and more efficiently serve oncology clients on the West Coast of the United States.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, announced today that it has entered into a definitive agreement to acquire Inform Diagnostics, a leading national independent pathology laboratory based in Irving, Texas, and a portfolio company of Avista Capital Partners. Under the terms of the agreement, Fulgent will acquire Inform Diagnostics for a total purchase price of approximately $170 million, subject to adjustments, to be paid from cash on hand. The acquisition is expected to close during the second quarter of 2022, subject to the satisfaction of customary closing conditions, including regulatory approvals.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent Genetics” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will release its first quarter 2022 financial results after the market closes on Tuesday, May 3, 2022. The company’s Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim, Chief Commercial Officer Brandon Perthuis, and Chief Medical Officer Dr. Larry Weiss will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced a strategic investment in Spatial Genomics, Inc. (“Spatial”), a leading developer of sequential fluorescence in situ hybridization (seqFISH) technology. Fulgent Genetics is investing up to $40 million to lead Spatial Genomics’ Series A financing, which totals approximately $56 million and also includes investments by 12 West Capital and other investors. Fulgent is also entering into commercial arrangements with Spatial to integrate Spatial Genomics’ seqFISH technology into Fulgent’s comprehensive genomic testing platform.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent Genetics,” “Fulgent,” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced financial results for its fourth quarter and full year ended December 31, 2021.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent Genetics” or the “company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will release its fourth quarter and full year 2021 financial results after the market closes on Wednesday February 23, 2022. The company’s Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim, Chief Commercial Officer Brandon Perthuis, and Chief Medical Officer Dr. Larry Weiss will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.

Helio Health (“Helio”) and its commercial partner, Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent”), today announced the commercial launch of HelioLiver™, a multi-analyte blood test that incorporates cell free DNA (cfDNA) methylation patterns and serum protein markers for the detection of hepatocellular carcinoma (HCC) – the most common form of liver cancer. HelioLiver can detect HCC at its earliest stages when lesions are still very small, an area where traditional standard-of-care imaging tools often fall short, with the potential to enable more curative treatment options known to increase five-year survival rates by up to 13 times compared to when cancer has metastasized.1,2

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today confirmed that the Company’s RT-PCR test for SARS-CoV-2, the virus that causes COVID-19, can successfully detect the recently emerged Omicron variant of the virus. In addition, Fulgent is confident that its Next Generation Sequencing (NGS) tests for COVID-19 can accurately identify the variant.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent Genetics” or the “company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced financial results for its third quarter ended September 30, 2021.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent Genetics” or the “company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that members of its management team are scheduled to virtually participate in the following investor conferences:

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it has launched an antibody test for COVID-19 which will specifically target neutralizing antibodies. The test will be available through the Company’s consumer initiated platform, Picture Genetics.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent Genetics” or the “company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will release its third quarter 2021 financial results after the market closes on Tuesday November 9, 2021. The company’s Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim, Chief Commercial Officer Brandon Perthuis, and Chief Medical Officer Dr. Larry Weiss will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will be partnering with the Houston Health Department and Houston-area public schools to provide COVID-19 testing to students during the current school year.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent” or the “company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced financial results for its second quarter ended June 30, 2021.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, and Helio Health (“Helio”), an AI-biotechnology company developing blood-based early cancer detection tests, today announced the companies have entered into a strategic partnership to commercialize Helio’s blood-based early cancer detection tests. In conjunction with the commercial strategic partnership whereby the company has secured exclusive commercial rights for laboratory develop tests (“LDTs”) in the U.S. and Canada, Fulgent has made a strategic investment in Helio.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it has acquired CSI Laboratories (“CSI”) to expand its presence in somatic molecular diagnostics and cancer testing.

In the headline and first paragraph, first sentence of release, the date should read: Monday, August 9, 2021 (instead of Thursday, August 5, 2021).

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that it will release its second quarter 2021 financial results after the market closes on Thursday, August 5, 2021. The company’s Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim, Chief Commercial Officer Brandon Perthuis, and Chief Medical Officer Dr. Larry Weiss will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent Genetics” or the “Company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that the Company has made an incremental strategic investment in FF Gene Biotech, the Chinese entity formed in 2017 through a Joint Venture (“JV”) between Fulgent Genetics, Xilong Scientific and Fuzhou Jinqiang Investment Partnership (FJIP). Fulgent has made a cash investment of approximately $19.0 million in the Chinese entity, which gives Fulgent a majority stake and controlling ownership of FF Gene Biotech.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent” or the “company”), a technology company providing large-scale COVID-19 testing services and comprehensive testing solutions through its scalable technology platform, today announced financial results for its first quarter ended March 31, 2021.

Fulgent Genetics, Inc. (NASDAQFLGT) (“Fulgent Genetics” or the “Company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced the appointment of Lawrence Weiss, M.D. as Chief Medical Officer, reporting to the Company’s Chief Executive Officer, Ming Hsieh. Dr. Weiss will be responsible for expanding Fulgent’s reach in molecular diagnostics and driving the advancement of the Company’s portfolio of oncologic testing solutions.